Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

UCB/Celltech Merger Nears Completion: Integration To Commence Under CEO Doliveux

This article was originally published in The Pink Sheet Daily

Executive Summary

Celltech's TNF inhibitor CDP-870 is crown jewel of $2.7 bil. acquisition; a BLA filing is expected in 2007. UCB CEO Roch Doliveux will continue to serve as chief executive, while Celltech CEO Goran Ando will become deputy CEO.

You may also be interested in...



UCB/Celltech Exec Chairman Will Be UCB Pharma’s Doliveux

Current UCB Group Executive Committee Chairman Georges Jacobs will be replaced by UCB Pharma CEO Roch Doliveux effective Jan. 1. Jacobs will chair the board of directors.

UCB/Celltech Exec Chairman Will Be UCB Pharma’s Doliveux

Current UCB Group Executive Committee Chairman Georges Jacobs will be replaced by UCB Pharma CEO Roch Doliveux effective Jan. 1. Jacobs will chair the board of directors.

Celltech Finds CDP-870 Partner In UCB; BLA Filing Expected By 2007

The licensing agreement gives Celltech a means through which to commercialize the TNF inhibitor should the companies' proposed $2.7 bil. merger agreement fall through. UCB/Celltech will be fifth largest biotech company worldwide.

Topics

UsernamePublicRestriction

Register

LL1134940

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel